Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular ...
Dove Medical Press
Poorer final vision was associated with poorer baseline BCVA and diagnosis of central retinal vein occlusion after adjustment for age and sex (p<0.001 and 0.012, respectively). Significant elevation of IOP was noted at 3 months in the PSTA group, but ...


Retinal Vein Occlusion Market Grows Pervasively with CAGR of 11.2% | Diagnosis – Optical Coherence Tomography ...
Medgadget (blog)
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...

and more »

Proliferative diabetic retinopathy revealed using OCT angiography
Healio
The differential diagnoses for DR include but are not limited to: central retinal vein occlusion, branch retinal vein occlusion, ocular ischemic syndrome, hypertensive retinopathy or radiation retinopathy, sickle cell retinopathy, sarcoidosis and ...


Medscape

Complications After Intravitreal Injection Aggravate
Medscape
VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and best practices at the upcoming American Society of Retina Specialists (ASRS) 2018 Annual ...


Retinal Vein Occlusion Market 2018 Hefty Growth with CAGR of 11.2% | Diagnosis as Optical Coherence Tomography ...
News Australia Today
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...
Global Retinal Vein Occlusion Therapeutics Market 2018 Competitive Situation and Trends, Mergers & Acquisitions ...theaerospacenews.com

all 3 news articles »

PR Newswire (press release)

RETINA-AI Releases the First Artificial Intelligence Mobile App for ...
PR Newswire (press release)
HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...
RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AIBioSpace (press release) (blog)

all 2 news articles »

Oculocare's Alleye® Receives FDA 510(k) Clearance for Monitoring Eyesight in AMD
PR Newswire (press release)
... of 55) and in patients with macular conditions including age-related macular degeneration (AMD), diabetic macular edema (DME) and central retinal vein occlusion (CRVO). Alleye received a CE mark in Europe in 2017 and FDA 510(k) clearance in the US.

and more »

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting
The Center for Biosimilars
In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT collected data and analyzed the effectiveness of this biosimilar product in the real-world setting in ...


Fairfield Current

$1.58 Billion in Sales Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Huntington National Bank Has $2.72 Million Holdings in Regeneron ...Baseball Daily Digest
Regeneron Pharmaceuticals Inc (REGN) Stake Lifted by ...BharataPress

all 36 news articles »

Quantitative Comparison of Retinal Vascular Features in Optical Coherence Tomography Angiography Images From ...
Healio
OCTA allowed better discrimination of central subfield and macular microvasculature as compared to FFA. Thus, there ... Evaluation of macular ischemia in eyes with branch retinal vein occlusion: An optical coherence tomography angiography study. Retina.

and more »

Global Placenta Growth Factor Market | Analysis, Industry Overview & Business Forecast 2018-2025
Healthcare Sector
The Placenta Growth Factor market research report analyzes the Global Placenta Growth Factor Market 2018 economy standing and prediction categorizes the Placenta Growth Factor market size by vital players, varieties of types, application and Placenta ...

and more »

Retinal Vein Occlusion Therapeutics Sales Market Outlook, Opportunity And Demand Analysis, Forecast 2018-2025
trueindustrynews.com
Pune, India—The report on Global Retinal Vein Occlusion Therapeutics Market delivers comprehensive overview of the global market along with the market elements such as market drivers, market trends, challenges and restraints. Our analysts have done ...

and more »

Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Shares Sold by Gateway Investment Advisers LLC
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF ...

and more »

Bel Marra Health

Central retinal vein occlusion (CRVO): Types, causes, symptoms, and treatment
Bel Marra Health
Central retinal vein occlusion (CRVO) refers to a medical condition of the eye where the main vein of the retina has become blocked. Much like other organs of the human body, our eyes also require a constant supply of oxygenated blood supplied by ...


Baseball Daily Digest

Regeneron Pharmaceuticals Inc (REGN) Receives $404.16 Average PT from Brokerages
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Healthcare Dashboard - UpdateSeeking Alpha
Oakmark Select Fund: Second Quarter 2018Seeking Alpha
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 17 news articles »

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

WPLG Local 10

Vasular condition leads to sudden sight loss
WPLG Local 10
Burgess was diagnosed with central retinal vein occlusion, or CRVO, a condition that causes a clot to form in the eye, leading to damaging pressure. "It was like someone threw a tomato at my eye," Burgess said. Cardiologist Dr. Adam Splaver said CRVO ...


Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Shares Bought by State of Alaska Department of Revenue
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Healthcare Dashboard - UpdateSeeking Alpha
Oakmark Select Fund: Second Quarter 2018Seeking Alpha
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 37 news articles »

Baseball Daily Digest

Regeneron Pharmaceuticals (REGN) Stock Rating Upgraded by BidaskClub
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to ...
Markets Insider
Ozurdex® is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular edema following BRVO and CRVO. Allergan has accelerated access to this treatment in 27 hospitals across China, making it available as a ...


Cardiovascular Business

Researchers confirm link between retinal vein occlusion, heart attack
Cardiovascular Business
The researchers further divided the RVO group into individuals with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Compared to people with neither form of RVO, the adjusted hazard ratios for CRVO and BRVO were 1.35 and ...


Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Expected to Post Quarterly Sales of $1.59 Billion
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Baseball Daily Digest

Regeneron Pharmaceuticals (REGN) Price Target Raised to $415.00 at Argus
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Healthcare Dashboard - UpdateSeeking Alpha
Oakmark Select Fund: Second Quarter 2018Seeking Alpha
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks

all 17 news articles »

Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
There are two types of retinal veins. We have one central vein as well as several smaller branch veins. There are also two types of retinal vein occlusion: central retinal vein occlusion and branch retinal vein occlusion. The only difference between ...


Fairfield Current

Joseph L. Goldstein Sells 2000 Shares of Regeneron Pharmaceuticals Inc (REGN) Stock
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Ozurdex for retinal vein occlusion approved in China
Healio
The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein occlusion, according to a press release from Allergan. Ozurdex (dexamethasone intravitreal ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Dispatch Tribunal

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion
GlobeNewswire (press release)
... Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 3 clinical trial (“TOPAZ ...
Clearside Biomedical Clears Hurdle For Late-Stage Eye Disease StudySeeking Alpha

all 84 news articles »

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related ...
Dove Medical Press
... short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO).

» Load more